Vector Science and Therapeutics Corp.

As of May 31, 2026, Vector Science and Therapeutics Corp. carries a market capitalization of 259.40M, placing it among publicly traded companies globally. Its enterprise value stands at 257.90M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2026, Vector Science and Therapeutics Corp. has 153.49M shares outstanding.

These figures are as of May 31, 2026.

As of May 31, 2026, Vector Science and Therapeutics Corp. maintains a current ratio of 4.73, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures are as of the close on October 22, 2026.

These figures cover the twelve months ended May 31, 2026.

These figures are as of May 31, 2026. Total book value stands at 2.76M, with working capital of 2.52M providing operational flexibility.

These figures cover the twelve months ended May 31, 2026. After subtracting -80,585.60 in capital expenditures, free cash flow totaled -1.20M - equivalent to -0.02 per share.